Genocea Biosciences Secures $30,000,000 Series C Financing

  • Feed Type
  • Date
  • Company Name
    Genocea Biosciences
  • Mailing Address
    161 First Street Cambridge, MA 02142
  • Company Description
    Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    The developer has been ramping up a Phase I/IIa study of its lead program–GEN-003–for herpes simplex virus-2.
  • M&A Terms
  • Venture Investor
    Bill & Melinda Gates Foundation
  • Venture Investor
    Johnson & Johnson Development Corporation
  • Venture Investor
    Skyline Ventures
  • Venture Investor
    Polaris Venture Partners
  • Venture Investor
    SR One
  • Venture Investor
    Lux Capital
  • Venture Investor
    Cycad Group
  • Venture Investor
    Auriga Partners
  • Venture Investor
    Morningside Group

Trending on Xconomy